
Physician/Epidemiologist/Associate professor @BrownMedicine Opinions are my own
United States
Joined May 2009
- Tweets109
- Following139
- Followers63
- Likes2.2K
Could tadalafil affect glaucoma risk? Our multinational study found a 22% higher risk of glaucoma among tadalafil users with LUTS. Important findings for both eye care and urology. #glaucoma #LUTS #RWE
bjo.bmj.com/content/early/20…
35
Our new study found that CKD Stage 3 or higher was associated with greater risks of progression to proliferative diabetic retinopathy and severe retinal complications, with stronger associations observed at more advanced CKD stages.
dom-pubs.onlinelibrary.wiley…
17
New editorial: As CGRP-targeted therapies gain widespread use for migraine prevention, understanding their potential impact on glaucoma and ocular health is an important emerging research priority. #CGRP #Glaucoma #Migraine
tandfonline.com/doi/10.1080/…
2
33
In our multinational real-world study, GLP-1RA use was associated with lower rates of incident AF, particularly among adults with diabetes. Findings from >220 healthcare organizations across 30 countries.
#GLP1 #AtrialFibrillation #Diabetes #Obesity diabetesresearchclinicalprac…
1
18
We found that GLP-1 receptor agonists were associated with a lower risk of age-related macular degeneration (especially dry AMD) in adults with diabetes and obesity compared with metformin or other weight-loss medications. #RWE #GLP1
amjmed.com/article/S0002-934…
14
Bevacizumab biosimilars diffused rapidly in Medicare Part B, reaching 61.3% market share in 2023 and generating an estimated $84.5M in savings. Adoption gaps across rural and urban communities remain. @JCOOP_ASCO #Biosimilars
ascopubs.org/doi/10.1200/OP-…
1
17
Are glaucoma drug spending disparities due to use or price?
Our Ophthalmology Glaucoma study finds differences are driven by price—not utilization in Medicare Part D.
Implications for policy & equity.
#Glaucoma #HealthPolicy
sciencedirect.com/science/ar…
15
Joey Weng, MD, MPH, FAAFP retweeted
A calcitonin gene-related peptide inhibitor appears to lower the three-year risk of incident #glaucoma in adults with #migraine: hubs.la/Q04nrPf-0
#NeuroTwitter #CGRP @AndrewGoLeeMD @brycechipmunk
Joey Weng, MD, MPH, FAAFP retweeted
Socioeconomic Differences in Glaucoma Medication Spending Under Medicare Part D: Evidence on Price vs Utilization
ow.ly/3bhO50Z7ctO
@brycechipmunk
#ophthalmology #glaucoma
Joey Weng, MD, MPH, FAAFP retweeted
Class II evidence that CGRP inhibitor (CGRPi) users with migraine have a lower risk of incident glaucoma when compared with non-CGRPi users with #migraine: hubs.ly/Q04jpjcG0
New in IOVS:
Denosumab (RANKL inhibitor) was linked to lower risk of OHT (HR 0.72) & POAG (HR 0.63) vs bisphosphonates.
Another signal connecting systemic therapy & eye disease.
#Glaucoma #IOVS #RealWorldData
iovs.arvojournals.org/articl…
11
Joey Weng, MD, MPH, FAAFP retweeted
Chien-Chih Chou from the National Yang Ming Chiao Tung University investigate RANKL inhibition and the risk of ocular hypertension and primary open-angle glaucoma.
doi.org/10.1167/iovs.67.6.8
In >14K patients with dry eye disease, omega-3 supplementation was linked to lower glaucoma risk
– POAG HR 0.45
– Total glaucoma HR 0.48
Another signal connecting metabolism & eye disease.
#Glaucoma #Omega3 #Ophthalmology
tvst.arvojournals.org/articl…
12
New in TVST:
PCSK9 inhibitors were associated with lower risk of AMD (esp. dry AMD) vs statins in a large real-world cohort.
More evidence linking lipid pathways & retinal disease—needs confirmation.
#AMD #PCSK9 #Ophthalmology
tvst.arvojournals.org/articl…
25
Our new study in Ophthalmology Glaucoma:
In >51K adults with T2DM, tirzepatide was associated with lower POAG risk vs GLP-1RAs (HR 0.65) over 2 years.
Promising signal—but needs confirmation.
#Glaucoma #Diabetes #Tirzepatide ophthalmologyscience.org/art…
38
Our prospective study found ETDQ-7 scores moderately correlated with SNOT-22 severity in CRS patients undergoing FESS, while objective ET function measures showed no significant group differences. #ENT #CRS #ETD
aao-hnsfjournals.onlinelibra…
1
59
Joey Weng, MD, MPH, FAAFP retweeted
📢 “While this does not support using #CGRP inhibitors for #glaucoma prevention, it provides additional safety reassurance and highlights a potential link between #migraine biology and ocular disease,” said @brycechipmunk.
Read the full summary here👇
vist.ly/54as3
Joey Weng, MD, MPH, FAAFP retweeted
📢 “#CGRP inhibitors do not appear to increase #glaucoma risk and may be associated with a modestly lower risk compared with other preventive therapies,” wrote @brycechipmunk.
#migraine @Healio_OSN
Read the full summary here👇
vist.ly/546ym
Joey Weng, MD, MPH, FAAFP retweeted
A new study co-authored by clinical associate professor of #FamilyMedicine, Chien-Hsiang Weng highlights a potential link between migraine treatment and reduced glaucoma risk.
The research found that adults using calcitonin gene-related peptide inhibitors (CGRPi), particularly monoclonal antibody therapies, experienced a lower risk of developing glaucoma compared with those using other preventive migraine medications.
Read the full study published by the American Academy of Neurology (AAN) Neurology Journal: neurology.org/doi/10.1212/WN…
Joey Weng, MD, MPH, FAAFP retweeted
New study published in @GreenJournal: Certain #migraine prevention drugs associated with reduced risk of #glaucoma. hubs.ly/Q04fJ9rG0
#AANscience #Neurology











